SCHEMBL16385302

SCHEMBL16385302

Cc1ccnc(-c2ccc(O)c(C)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.55
CCR5 P51681 1/20 0.55
CCR8 P51685 1/20 0.55
TP53 P04637 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CYP2A6 P11509 1/20 0.49
TLR8 Q9NR97 3/20 0.48
HSD17B1 P14061 5/20 0.45
HSD17B2 P37059 5/20 0.45
METAP2 P50579 1/20 0.45
CDC7 O00311 1/20 0.44
PIM1 P11309 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CLK1 P49759 1/20 0.44
GSK3B P49841 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
CSNK2A3 Q8NEV1 1/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27842922 0.83 CCR1 (0.61) CCR1CCR5CCR8CYP2A6METAP2
SCHEMBL16385239 0.83 TLR8 (0.57) TLR8HSD17B1HSD17B2CDC7PIM1
SCHEMBL27344644 0.80 CCR1 (0.76) CCR1CCR5CCR8CYP2A6METAP2
SCHEMBL31695263 0.80 CCR1 (0.76) CCR1CCR5CCR8CYP2A6METAP2
SCHEMBL17406767 0.79 CCR1 (0.61) CCR1CCR5CCR8CYP2A6METAP2
SCHEMBL172718 0.79 HSD17B1 (0.51) CCR1CCR5CCR8TLR8HSD17B1
SCHEMBL19248553 0.79 CCR1 (0.55) CCR1CCR5CCR8CYP2A6METAP2
SCHEMBL16385300 0.77 HSD17B1 (0.47) TLR8HSD17B1HSD17B2CDC7PIM1
Bromide SCHEMBL17744696 0.77 HSD17B1 (0.50) CCR1CCR5CCR8TLR8HSD17B1
SCHEMBL17788166 0.77 KDM4E (0.53) TLR8HSD17B1HSD17B2CDC7PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020715-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2021-06-16 EP disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
WO-2015005499-A1 TETRAZOLINONE COMPOUND AND USE THEREOF 住友化学株式会社 (JP) 2015-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SOD1, UQCRB, MT-CO1 CCR1 1629/4885CCR5 2680/4885CCR8 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.